Explore By Subject Area   

Lead Editorial

Leveraging a US-Chinese Biotech Collaboration to Develop a PD-1/VEGF Bispecific Antibody

Leveraging a US-Chinese Biotech Collaboration to Develop a PD-1/VEGF Bispecific Antibody

Allen Yang, MD, PhD, CMO of Summit Therapeutics discusses the clinical development strategy for Ivonescimab, the difference between Western and Chinese innovation and navigating international regulatory interactions.

Read More

More Related Content

Editorial

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.